Blog page

See interview published in today's Jerusalem Post with Dr. Nitsan Maharshak, Head of Bacteriotherapy Clinic at Tel Aviv Medical Center and Co-Chairperson of the Microbiome track at the IATI-Biomed 2016 conference, May 24-26 (print version attached pdf): It seems that while Creator allowed a wide variety of diseases to inflict mankind, He also provided [...]

Innovative Biomed startups are invited to showcase their technologies and participate in the startup competition at IATI-Biomed, May 24-26, Tel Aviv IATI-Biomed conference and exhibition, Israel's leading annual life science industry meeting Israel’s premier international biomed conference and exhibition, IATI-Biomed 2016, will celebrate its 15th anniversary on May 24-26, at the David InterContinental Hotel [...]

Technology can bring modern medicine anywhere in the world, if the phone system is working, but humans have to remain in control, says Technion professor Alon Wolf   Breakthrough device helps MRI take better snapshot of stressed heart Kibbutzim in the new millennium: Cultivating high-tech China’s new vision of manufacturing welcomes Israeli startups As the [...]

Israeli scientists are being introduced to a new technique to cure some genetic diseases by a Tel Aviv University biologist and geneticist. Anyone familiar with a word-processing program has much experience cutting and pasting for editing text and even images. Although “gene editing” for eventually treating and even curing human diseases is almost unknown to [...]

Call for Abstracts  Deadline extended for Oral Company Presentations till April 10 at IATI Biomed 2016 Dear Colleagues, IATI Biomed 2016 is the premier life sciences event providing a meeting place for the healthcare’s industry players from Israel and abroad. For the 15th  consecutive year, this world-class event offers a professional conference with world-renowned speakers, a must-attend functional exhibition and a [...]

NEW HAVEN, Conn., March 16, 2016 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced positive results from its HOPEMD Phase 2 six-month open-label clinical study in patients with oculopharyngeal muscular dystrophy (OPMD), a rare progressive muscle-wasting disease characterized by swallowing difficulties (dysphagia), leading to the risk of aspiration of [...]

  The company already has distribution agreements in Israel, Sweden, Australia, and New Zealand. The system developed by Israeli company Emerald Medical Applications (OTC: MRLA), formerly DermaCare, which is designed to diagnose melanoma, has been approved for marketing by the US Food and Drug Administration (FDA). Emerald's market cap is $10 million, following its merger [...]

The Start-up Pavilion Submission Deadline is March 22nd, 2016 If you’re an innovative early stage Biomed start-up, this is for you! One of the highlights of the IATI Biomed Exhibition is the Start-up Pavilion, dedicated to providing a powerful, high-end platform for maximum exposure and business development opportunities for innovative start-up companies. Strategically located at [...]